The Problematization of Sexuality among Women Living with HIV and a New Feminist Approach for Understanding and Enhancing Women’s Sexual Lives

In the context of HIV, women’s sexual rights and sexual autonomy are important but frequently overlooked and violated. Guided by community voices, feminist theories, and qualitative empirical research, we reviewed two decades of global quantitative research on sexuality among women living with HIV. In the 32 studies we found, conducted in 25 countries and composed mostly of cis-gender heterosexual women, sexuality was narrowly constructed as sexual behaviours involving risk (namely, penetration) and physiological dysfunctions relating to HIV illness, with far less attention given to the fullness of sexual lives in context, including more positive and rewarding experiences such as satisfaction and pleasure. Findings suggest that women experience declines in sexual activity, function, satisfaction, and pleasure following HIV diagnosis, at least for some period. The extent of such declines, however, is varied, with numerous contextual forces shaping women’s sexual well-being. Clinical markers of HIV (e.g., viral load, CD4 cell count) poorly predicted sexual outcomes, interrupting widely held assumptions about sexuality for women with HIV. Instead, the effects of HIV-related stigma intersecting with inequities related to trauma, violence, intimate relations, substance use, poverty, aging, and other social and cultural conditions primarily influenced the ways in which women experienced and enacted their sexuality. However, studies framed through a medical lens tended to pathologize outcomes as individual “problems,” whereas others driven by a public health agenda remained primarily preoccupied with protecting the public from HIV. In light of these findings, we present a new feminist approach for research, policy, and practice toward understanding and enhancing women’s sexual lives—one that affirms sexual diversity; engages deeply with society, politics, and history; and is grounded in women’s sexual rights

EFFECTS OF HONEST AND DISHONEST PRE-EXERCISE PLACEBO INGESTION ON VO2PEAK AND ISOMETRIC HANDGRIP PERFORMANCE

Jessica Moon1, Christian Espitia2, Landon Hiebert2, Christopher A. Fahs2, Lindy M. Rossow2 1Lindenwood University, St. Charles, Missouri; 2Lindenwood University-Belleville, Belleville Illinois Pre-exercise consumption of placebo has been shown to improve resistance and endurance exercise performance. However, the effects of placebo ingestion on graded exercise test performance have not been widely reported in the literature. PURPOSE: The purpose of this study was to examine the effects of honest (subjects were told they were consuming placebo) or dishonest (subjects were told they were consuming a pre-workout supplement) placebo ingestion on VO2peak values determined during a maximal treadmill graded exercise test. A secondary purpose of this study was to examine the effects of placebo consumption on isometric handgrip performance. We hypothesized that pre-exercise ingestion of both placebo conditions would result in increased VO2peak and handgrip performance compared to control. METHODS: 28 males (178.4 ± 6.94 cm, 83.3 ± 14.8 kg, 22.6 ± 2.3 yrs.) and 13 females (166.4 ± 8.49 cm, 73.6 ± 20 kg, 26.4 ± 11 yrs.) participated in this study. In a randomized, cross-over design, subjects performed treadmill VO2peak and isometric handgrip testing after consumption of honest placebo (HP) or dishonest placebo (DP). In addition, a third baseline trial (CON) was performed to establish performance values that were unaffected by a perceived placebo effect due to supplementation. All outcomes were assessed for normality using the Shapiro-Wilks test. When assumptions of normality were violated, log transformations were computed. However, transformations did not improve model assumptions. Therefore, non-transformed data is reported. One-way ANOVAs were used to analyze VO2peak and handgrip strength data across conditions. Alpha was set at 0.05 prior to all analyses. RESULTS: Significant between-groups differences (p \u3c 0.05) were not detected for relative VO2peak (CON = 46.2 ± 9.3 mL/kg/min; HP = 46.7 ± 10 mL/kg/min; DP = 46.6 ± 9.6 mL/kg/min) or for maximal handgrip strength (CON = 43 ± 9.6 kg; HP = 44.1 ± 12.4 kg; DP = 43.4 ± 12.1 kg). CONCLUSION: Administration of honest or dishonest placebo immediately prior to VO2peak and handgrip testing had no effect on performance compared to control. The VO2peak and isometric handgrip tests were found to be robust exercise tests not significantly influenced by perceived pre-workout supplement consumptio